Vancouver-based CereCura Nanotherapeutics is pursuing a new approach to treating neurological disorders using lipid nanoparticle RNA technology, the same platform behind leading COVID-19 vaccines.
Spun out of the University of British Columbia, the pre-clinical startup recently secured $1.4 million in seed funding—led by WUTIF Capital and supported by eFund, UBC Venture Funds, angels, and Hextwo Capital—to validate its lead drug candidate in rodents and later larger animals. Co-founded by LNP pioneer Pieter Cullis and CEO Louis-Philippe Bernier, the company has already shown successful protein delivery to rodent brains, addressing the long-standing barrier posed by the blood-brain barrier.
Want to know more? Check out the source code on BetaKit.